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More than 1.9 billion adults are overweight or obese, repre-senting over one third of the world-wide adult population1. The biggest health and economic burden of obesity is the 
large number of obesity-related co-morbidities. In addition to type 
2 diabetes and cardiovascular disease, obesity is associated with an 
increased risk of cancer and infections2–4. Indeed, up to 49% of cer-
tain types of cancer are now attributed to obesity3, and weight loss 
through bariatric surgery can reverse cancer risk5. Potential mecha-
nisms for the increased risk of cancer associated with obesity include 
overproduction of hormones (for example, oestrogens), adipokines 
(for example, leptin), and insulin, which favor cell proliferation 
and tumor growth6,7. Peroxisome proliferator-activated receptors 
(PPARs) are transcriptional regulators of cellular metabolism. It 
has recently been shown that obesity induces a PPAR-driven lipid 
metabolism program in metastatic tumor cells, which enhances 
metastasis and tumor cell survival8. In intestinal stem cells, obesity-
driven PPAR signaling enhances stemness and tumor progression9. 
However, despite the increasing attention to the role of the immune 
system and inflammation in obesity-driven insulin resistance, the 
impact of obesity-induced dysfunction on immunosurveillance and 
cancer risk is not well understood.
Natural killer (NK) cells have crucial roles in protective immu-
nity against tumors and viral infections10. NK cells kill their targets 
through the directed secretion of lytic granules, which contain 
pore-forming perforin and apoptosis-inducing granzymes11–13. 
Cellular metabolism has a critical role in the function of immune 
cells. NK cells switch the balance of the core metabolic program 
from oxidative phosphorylation (OXPHOS) to glycolysis to meet 
the increased energy required to kill tumor cells14,15, although the 
steps in the killing process that require this metabolic activation 
are unknown.
Humans and mice with obesity display numerical and functional 
defects in NK cells and have an increased risk of cancer and infec-
tions. As obesity is a state of altered metabolism, we investigated the 
effect of obesity on the cellular metabolism, gene expression, and 
function of NK cells, and its contribution to cancer development. 
Our data show that NK cell uptake of lipids from the environment in 
human obesity interfered with their cellular bioenergetics, inducing 
‘metabolic paralysis’. Lipid-induced metabolic defects caused NK 
cell incompetence by inhibiting trafficking of the cytotoxic machin-
ery, leading to loss of antitumor functions in vitro and in vivo. Our 
data suggest that obesity targets immunometabolic pathways and 
that this may be partly responsible for the increased cancer and 
infection risks in obesity, and suggest that metabolic reprogram-
ming may improve innate immunosurveillance in obesity.
Results
Obesity induces lipid metabolism in NK cells. To better under-
stand the effects of obesity on NK cells, we examined mouse 
models of diet-induced obesity. We performed transcriptional anal-
ysis of NK cells from mice fed a short-term (1 week) or long-term 
(8 weeks) high-fat diet (HFD), and compared this with transcrip-
tional analysis of NK cells from mice fed a standard-fat diet (SFD). 
Gene expression analysis revealed that after just 1 week of HFD, 
NK cells upregulate 107 genes, the majority of which are related 
to lipid handling and metabolism (Fig. 1a). After 8 weeks of HFD, 
NK cell gene expression was changed substantially, with differen-
tial expression of 3,000 genes compared to SFD-fed mice (Fig. 1b). 
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Many lipid handling and lipid metabolism genes were overex-
pressed in obesity, chief among them being Ldlr, Cd36, genes 
encoding fatty acid–binding proteins (FABPs), and Cpt1b. Genes 
highly downregulated included Prf1 and genes encoding granzymes 
(Fig. 1b). Gene pathway analysis revealed that the most downregu-
lated pathway was NK cell–mediated cytotoxicity. Genes involved in 
mechanistic target of rapamycin (mTOR) signaling were also down-
regulated (Fig. 1c). Highly upregulated pathways in NK cells in obe-
sity included PPAR signaling and glycerolipid metabolism pathways 
(Fig. 1d). Indeed, the expression of genes involved in lipid-droplet 
formation and lipases (Lipe and Plin2), lipid and glycerol uptake 
(Cd36, Lpl, and Lrp4) and lipid metabolism (Abca1, Scarb2, and 
Gyk) was increased in NK cells from HFD mice. Interestingly, these 
were all PPARα /δ target genes (Fig. 1a,b). PPARα /δ are fatty acid–
regulated transcription factors that control lipid metabolism and are 
turned on in the presence of free fatty acid (FFA) ligands. In obe-
sity, there is a chronic elevation of FFA in the circulation16,17. These 
data suggest that obesity induces metabolic reprogramming in NK 
cells to lipid metabolism, which inhibits the expression of NK cell 
effector molecules.
NK cells are dysfunctional in human obesity. To investigate 
whether human obesity has the same effects as mouse obesity on NK 
cells, we studied NK cells from lean and obese age-matched indi-
viduals. Individuals with obesity were deficient in NK cell numbers 
and function. Consistent with previous studies18–21, the frequency 
of circulating NK cells (CD3−CD56+) was significantly lower in 
obese individuals than in lean individuals (Fig. 2a). Moreover, we 
found that NK cells from obese individuals killed significantly fewer 
tumor cells (Fig. 2b) and produced significantly less interferon-γ 
(IFN-γ ) compared with NK cells from lean individuals, as measured 
by flow cytometry (Fig. 2c) and by ELISA (Fig. 2d). Our studies with 
HFD in mice revealed a link between lipid metabolism and loss of 
cytotoxicity in NK cells. We next demonstrated that the same path-
ways were altered in NK cells in human obesity. Consistent with our 
findings in mice, we observed higher CD36 surface expression on 
NK cells from obese individuals than on those from lean individuals 
(Fig. 2e), suggestive of PPARα /δ pathway activation. Moreover, NK 
cells from obese individuals stained more strongly for lipids than 
those from lean donors (Fig. 2f). Microscopy revealed greater intra-
cellular lipid droplet accumulation in NK cells from obese individu-
als than from lean individuals; NK cells from lean donors only stained 
for plasma membrane lipids (Fig. 2g). Thus, our results suggest that 
NK cells turn on PPARα lipid metabolism pathways in response to 
the lipid-rich environment in obesity. As in obese mice, NK cells 
from humans with obesity had lower expression of granzymes 
and perforin at the mRNA and protein level than lean individuals 
(Fig. 2h–j). Collectively, our data show that human obesity is associ-
ated with reduced NK cell cytotoxic effector functions.
Lipid uptake inhibits human NK cell functions. As NK cells from 
obese individuals displayed increased lipid accumulation, we inves-
tigated whether intracellular lipid accumulation is causally linked 
to the loss of function in human NK cells. There is a chronic eleva-
tion of FFA, particularly palmitate, in the circulation in obesity16,17. 
When human NK cells from lean controls were cultured with FFA 
(palmitate and/or oleate), they readily incorporated FFA from the 
media (Fig. 3a). Microscopy revealed that FFA-cultured NK cells had 
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accumulated intracellular lipid droplets (Fig. 3b). Notably, NK cells 
that accumulated lipid droplets displayed a loss of perforin granules 
(Fig. 3b). The NK cells that accumulated the most lipids had little or 
no detectable perforin, whereas cells that took up fewer lipids had 
higher levels of perforin granules (Fig. 3b). Loss of perforin and gran-
zyme B after FFA culture was detected by flow cytometry (Fig. 3c). 
Lipid accumulation in NK cells also led to loss of cytotoxicity 
against tumor cells (Fig. 3d and Supplementary Fig. 1a). FFA can be 
cytotoxic in certain cells, but at this concentration, lipid treatment 
did not affect the viability of NK cells (Supplementary Fig. 1b). NK 
cells pre-cultured with FFA also produced significantly less IFN-γ , 
in a dose-dependent manner (Fig. 3e and Supplementary Fig. 1c). 
We also tested whether other features of obesity could induce the 
loss of NK cell effector functions, including high glucose or high 
insulin concentrations, but unlike FFA culture, these conditions did 
not affect the ability of NK cells to kill target cells. Together, these 
results indicate that the lipid uptake and accumulation seen in NK 
cells from individuals with obesity blunts NK cell function.
The mTORC1 pathway is impaired in obesity. The protein kinase 
mechanistic target of rapamycin complex 1 (mTORC1) coordinates 
the metabolic activities of the cell in response to nutrients and 
growth factors22. Downstream targets and pathways of mTORC1 
include granzyme expression23 and glycolysis in T cells. The 
mTORC1 pathway is also crucial for NK cell function, particularly 
IFN-γ production14,15, whereas less is known about mTORC1 and 
cytotoxic activity in NK cells. As mTORC1 activation is required 
for NK cell function, we reasoned that mTORC1 is inhibited in obe-
sity or by lipid uptake. Primary human NK cells treated with the 
mTORC1 inhibitor rapamycin produced less IFN-γ (Supplementary 
Fig. 2a), confirming previous reports14. In addition, tumor killing 
by NK cells was significantly reduced in rapamycin-treated cells, 
and after treatment with SL0101-1, which inhibits the downstream 
target of mTORC1, the ribosomal S6 kinase (S6K) (Fig. 4a). These 
data confirm the requirement of mTORC1 for NK cell cytotoxic 
effector function.
Activation of mTORC1 is associated with its own phosphory-
lation and its localization at the lysosomal membrane. Confocal 
analysis revealed that mTOR localized with perforin and CD107a, 
illustrating that mTOR localizes with lytic granules (Supplementary 
Fig. 2b). NK cell activation with interleukin 2 (IL-2) and IL-12 
resulted in increased phosphorylated mTOR (p-mTOR) expression, 
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Fig. 2 | Obesity leads to NK cell loss of function and lipid accumulation. a, Dot plots and numbers of NK cells CD56+ and CD3− from blood of lean (n =  32) 
and obese (n =  50) individuals. Numbers indicate the percentage of NK cells. Representative plots are shown. b, Cytotoxicity assay with NK cells from blood 
of lean (n =  27) and obese (n =  27) individuals co-incubated with target cells. c, Frequency of IFN-γ -positive NK cells stimulated with IL-2 and IL-12 (IL-2/
IL-12) measured by flow cytometry (n =  10 samples from lean individuals; n =  21 samples from individuals with obesity). d, NK cells were stimulated with 
IL-2/IL-12 and supernatants were analyzed for IFN-γ by ELISA (n =  12 samples from lean individuals, n =  12 samples from individuals with obesity). e, CD36 
expression in NK cells from blood of lean (n =  8) and obese (n =  8) individuals determined by flow cytometry. Numbers indicate mean fluorescence intensity 
(MFI). f, Lipids level of NK cells from lean (n =  9) and obese (n =  24) individuals measured by lipidTOX staining by flow cytometry. Numbers indicate MFI. 
g, Confocal images of NK cells isolated from the blood of lean and obese donors and stained with Bodipy 495/515. Representative of two independent 
experiments. h, GZMB and PRF1 mRNA levels in NK cells isolated from blood of lean and obese individuals (n =  6 per group). i,j, Frequency of PRF-1-positive 
(i) and GZMB-positive (j) NK cells from blood of lean (n =  13) and obese (n =  45) individuals. Scale bar represents 10 μ m. Each symbol represents one 
individual. Short horizontal bars indicate the mean ±  s.e.m. Statistics were calculated using a Student’s unpaired t-test. *P <  0.05, **P <  0.01, ***P <  0.001.
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which colocalized with lytic granules (lysosome-related organelles). 
As a control, mTOR was not phosphorylated in starvation media 
or in the presence of mTOR inhibitor Torin 1 (Fig. 4b). We next 
analyzed p-mTOR expression in lipid-treated NK cells by confo-
cal microscopy. Compared with untreated NK cells, FFA-treated 
NK cells displayed a marked reduction in p-mTOR at lytic gran-
ules (Fig. 4c). We also measured mTORC1 activation via the down-
stream phosphorylation of S6 (p-S6) by S6K, by flow cytometry. 
Primary human NK cells from lean controls pre-treated with lipids 
displayed significantly less p-S6 after cytokine stimulation (Fig. 4d  
and Supplementary Fig. 2c) and after encountering tumor cells 
(Fig. 4e). We analyzed the level of mTORC1 activation in NK cells 
freshly isolated from obese and lean individuals. There was signifi-
cantly less p-S6 in NK cells from obese compared to lean individu-
als after cytokine stimulation (Fig. 4f). Together, our findings show 
that a lipid-rich environment, such as in obesity, inhibits mTORC1 
activation in human NK cells, which inhibits their effector function.
NK cell metabolism is impacted negatively during obesity. 
Cellular metabolism has a critical role in the effector function of 
immune cells, including NK cells. mTORC1 activation leads to an 
increase in aerobic glycolysis in NK cells, a requirement for full 
effector function14,15. As obesity is a state of altered metabolism, and 
mTORC1 activation is impaired in obesity, we investigated the effect 
of obesity on the cellular metabolism of human NK cells. We first 
measured the uptake of fluorescent glucose analog 2-NDBG in NK 
cells. NK cells pre-treated with lipids had significantly less 2-NBDG 
uptake when stimulated with cytokines (Fig. 5a) or with tumors 
than untreated NK cells (Supplementary Fig. 3a). Moreover, NK 
cells isolated ex vivo from individuals with obesity had significantly 
less 2-NDBG uptake when stimulated with cytokines than NK 
cells from lean individuals (Fig. 5b). In support of these findings, 
transcriptional data from NK cells of obese mice showed downregu-
lation of many glycolytic genes compared with NK cells of lean mice 
(Supplementary Fig. 3b). To determine the effects of lipid uptake 
on bioenergetics in NK cells, we measured the oxygen consumption 
rate (OCR) and extracellular acidification rate (ECAR), which cor-
respond to OXPHOS and aerobic glycolysis, respectively. We found 
that lipid pre-treatment significantly impaired the ability of NK 
cells to induce both glycolysis and OXPHOS after stimulation, and 
reduced their glycolytic capacity (Fig. 5c–e). Due to the inhibition 
of both glycolysis and OXPHOS, NK cells treated with lipids gener-
ated significantly less ATP (Fig. 5f). To confirm that these findings 
reflected the situation in human obesity, we measured bioenerget-
ics of NK cells freshly isolated from obese and lean individuals. 
The basal metabolism of unstimulated NK cells is similarly low in 
both lean and obese individuals; however, cytokine stimulation of 
NK cells from lean individuals increased the rate of both glycolysis 
and OXPHOS to meet the increased metabolic demand, consistent 
with previous studies14. In contrast, stimulated NK cells from indi-
viduals with obesity had a substantially blunted metabolic response 
(Fig. 5g,h). Glycolysis and the glycolytic capacity were substan-
tially lower in NK cells from individuals with obesity than lean 
individuals (Fig. 5g,i). Moreover, NK cells from obese individuals 
did not increase the rate of OXPHOS when stimulated, unlike NK 
cells from lean controls (Fig. 5h,i). We next asked whether similar 
metabolic defects were seen in NK cells in obese mice. Similar to 
humans, mice fed a HFD for 13 weeks had functionally defective 
NK cells that produced significantly less IFN-γ (Fig. 5j). NK cells 
isolated from obese mice displayed significant metabolic defects, 
including significantly lower p-S6 expression after activation 
(Fig. 5k), and significantly reduced glycolytic capacity, OXPHOS, 
and maximum respiration rate (Fig. 5l–q). Together, these results 
highlight that human and murine obesity are associated with severe 
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cellular metabolic defects in NK cells, including a failure to activate 
both glycolytic and oxidative metabolic pathways, representing a 
type of metabolic paralysis. These metabolic and functional defects 
can be mimicked by culturing NK cells with FFAs, which is likely to 
underlie NK cell dysfunction in obesity.
The PPARα/δ pathway contributes to NK cell defects in obe-
sity. Our data from mice and humans show that obesity-induced 
expression of PPAR target genes that encode proteins involved in 
lipid metabolism, increase lipid uptake and inhibition of the mTOR 
pathway. It has been reported that activation of the mTOR pathway 
inhibits PPAR lipid pathway targets24–26. Conversely, we investi-
gated whether activation of PPAR pathways in NK cells can inhibit 
mTOR, leading to obesity-induced defects in NK cells. Human 
NK cells expressed PPARA and PPARD, but not PPARG (Fig. 6a). 
Treatment of NK cells from lean controls with PPARα and PPARδ 
agonists induced lipid uptake from the media, and significantly 
reduced the expression of perforin (Fig. 6b). Furthermore, when 
NK cells were cultured with FFA, addition of PPARα /δ antagonists 
prevented lipid accumulation and the loss of perforin (Fig. 6c). 
Thus, PPAR α /δ agonists mimicked the effects of obesity on NK 
cell function. We next tested whether PPARα /δ agonists affected 
NK metabolism. Treatment of NK cells from lean individuals with 
PPARα /δ agonists significantly inhibited p-S6, similar to FFA 
treatment, and PPARα /δ antagonists reversed the effects of FFA 
treatment (Fig. 6d). Furthermore, NK cells isolated from lean indi-
viduals treated with PPARα /δ agonists displayed lower glycolysis 
and glycolytic capacity than untreated NK cells (Fig. 6e). We next 
verified whether murine NK cells were similarly affected by PPAR 
pathway induction. NK cells isolated from spleens of lean mice 
treated with PPARα /δ agonists produced significantly less IFN-γ 
(Fig. 6f) and tended to have lower granzyme B expression (Fig. 6g) 
than untreated controls. Lean NK cells treated with PPARα /δ ago-
nists displayed significantly blunted glycolytic capacity (Fig. 6h,j–l), 
and surprisingly, a significantly impaired maximal respiration 
rate (Fig. 6i,m,n) than untreated NK cells. Downstream signal-
ing, including that of c-Myc (which is critical for NK cell metabo-
lism) and p-S6, was inhibited in activated NK cells after treatment 
with PPARα /δ agonists (Fig. 6o). Thus, the upregulation of 
PPAR pathways in NK cells in obesity inhibits mTOR signaling, 
activation-induced metabolic reprogramming, and effector mol-
ecule expression in human and mouse NK cells.
Mechanism of NK cell cytotoxic dysfunction in obesity. Obesity-
induced metabolic paralysis in NK cells results in loss of cytotoxic 
activity, but it is unknown which step (or steps) in the cytotoxic 
pathway require metabolic activation or are affected by obesity. 
NK cell cytotoxicity occurs in a stepwise controlled manner11,12, 
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whereby NK cells form conjugates and a synapse with tumor cells, 
sending an activating signal to NK cells27,28, inducing lytic gran-
ules to concentrate around the microtubule-organizing center 
(MTOC)29,30. Next, the lytic granules and MTOC are directed to 
the synapse, and their lytic content is released in a targeted manner 
into the synapse, which is essential for effective killing of tumor 
cells31–33. We investigated the stepwise process of cell killing in obe-
sity to better understand the impact of altered metabolism, and 
hence obesity, on cytotoxicity.
First, we examined whether NK cells can recognize tumor cells in 
obesity, by measuring the presence of a synapse and the concentra-
tion of the adhesion protein CD2 at the synapse by confocal micros-
copy. Pre-treatment with lipids did not affect the ability of NK cells to 
form a conjugate and synapse with tumor targets (Fig. 7a), suggesting 
that NK cells do not require metabolic activation to recognize tumor 
cells or rearrange their actin filaments to form a synapse. We next 
measured polarization of the MTOC and found that lipid-treated 
NK cells were unable to polarize the MTOC towards the tumor 
cells, despite an intact synapse (Fig. 7a). The Golgi apparatus, which 
is associated with the MTOC11,34, also did not polarize at the synapse 
(Fig. 7b). Similarly, NK cells from individuals with obesity formed 
a conjugate and synapse with tumor target cells but failed to polar-
ize their MTOC and lytic granules to the synapse, whereas NK cells 
from lean controls were able to do so (Fig. 7c). Thus, obesity does 
not affect the ability of NK cells to recognize tumor cells or form 
an immune synapse but strongly impedes the ability of NK cells to 
direct lytic granules to the tumor cell and degranulate at the syn-
apse, which is critical for efficient killing of tumor cells.
The inability of NK cells from obese individuals to mobilize their 
lytic machinery to the tumor, and their impaired mTORC1 activa-
tion, suggest that metabolic activation is required for this step. To 
test this, NK cells were treated with the mTOR inhibitors rapamycin 
or Torin 1 prior to incubation with tumors. Inhibition of mTOR did 
not affect the ability of NK cells to recognize or form conjugates with 
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tumor cells, but resulted in significantly fewer polarized NK cells 
(Fig. 7d and Supplementary Fig. 4). Blocking glycolysis in NK cells 
with the competitive glycolytic inhibitor 2-DG (2-deoxy-d-glucose) 
also inhibited NK cell polarization and tumor killing, despite nor-
mal tumor cell recognition and synapse formation (Fig. 7e). NK cell 
proliferation also requires MTOC polarization. We examined the 
effects of a lipid-rich environment in obesity and found that FFA 
treatment significantly impaired NK cell proliferation in mice and 
humans (Supplementary Fig. 5a,b). NK cells isolated from individ-
uals with obesity did not expand in culture or when treated with 
PPAR agonists, unlike control NK cells (Supplementary Fig. 5c,d). 
Thus, lipid pathway induction and obesity impair the ability of NK 
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cells to proliferate, which may partly explain the reduced NK cell 
numbers in obesity. Together, our results demonstrate that obesity-
induced NK cell functional defects are due to induction of lipid 
pathways, impaired metabolism, and mTORC1 inhibition, which 
inhibit intracellular trafficking in NK cells.
Reversal of metabolic defects restores NK cell cytotoxicity. Our 
data suggest that reversing metabolic defects in NK cells in obesity 
might restore cytotoxicity. The fatty acid translocase gene Cpt1, 
which transports fatty acids to the mitochondria, was among the 
lipid-related genes upregulated in obesity (Supplementary Fig. 3b). 
Blocking fatty acid transport can induce a metabolic switch from 
OXPHOS to glycolysis. Although both glycolysis and OXPHOS 
were defective in obesity, previous studies have shown that glycol-
ysis has an important role in NK effector functions. We therefore 
reasoned that blocking CPT1b may increase glycolysis, and thereby 
restore NK cell cytotoxicity. Bioenergetics of NK cells treated with 
lipids were measured in the presence of the CPT1b inhibitor eto-
moxir. Although the glycolytic rate was blunted after lipid treat-
ment, the addition of etomoxir significantly increased the rate of 
glycolysis in NK cells (Fig. 7f,g). As a control, we measured the OCR 
after etomoxir treatment and demonstrated that this was reduced 
as expected due to blocking of CPT1b (Fig. 7f,g). Importantly, 
etomoxir restored NK cell cytotoxicity (Fig. 7h). If the defect in cyto-
toxicity was due to inability to activate glycolysis to polarize lytic 
granules upon tumor encounter, then restoring glycolysis should 
restore the ability to polarize the MTOC and lytic machinery to the 
synapse. Indeed, etomoxir treatment did not change the number of 
NK cell–tumor conjugates; however, it significantly increased the 
percentage of polarized NK cells with their MTOC and lytic gran-
ules at the immunological synapse and therefore increased tumor 
killing (Fig. 7i,j). Thus, metabolic defects associated with lipid 
uptake can be restored, and this meets the metabolic requirements 
for NK cells to assume their cytotoxic function.
Lipid-treated NK cells fail to control tumor growth in vivo. 
Lipid accumulation was seen in NK cells in vivo in both human 
and murine obesity, and lipid accumulation led to loss of cytotoxic 
function in vitro. We next determined the effect of obesity-induced 
defects on tumor growth in vivo. Lipid treatment of splenic NK cells 
completely inhibited their ability to produce IFN-γ when stimulated 
with IL-12, IL-15, and IL-18 (Fig. 8a). Next, we asked whether lipid 
uptake inhibited the ability of NK cells to efficiently kill tumor cells 
in vivo, using a B16F10 melanoma model. Lipid-treated or con-
trol NK cells were activated with IL-12, IL-15, and IL-18, and were 
injected peritumorally into B16 tumor–bearing mice on days 3, 7, 
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12 weeks and at week 10, B16 tumor were injected s.c. into the flank (n =  5 mice per group). Data show weight gain (e) and tumor growth (f). On day 15 post 
tumor induction, tumors were isolated and the NK cell frequency (g), density (h,i) and IFN-γ production were analyzed by flow cytometry (j). In c, d, and 
g–j, each symbol represents one individual mouse. Small horizontal bars indicate the mean (± s.e.m). Statistics were calculated using a Student’s unpaired 
t-test (c,d,g,h,j) or a two-way ANOVA followed by a Bonferroni test (b,e,f) to analyze each replicate. *P <  0.05, **P <  0.01, ***P <  0.001. ns, not significant.
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and 11 post tumor induction. Transfer of stimulated control NK 
cells significantly reduced the tumor burden, whereas stimulated 
lipid-treated NK cells had no impact on tumor burden; there was no 
difference in tumor growth in mice injected with lipid-treated NK 
cells or mice injected with PBS buffer (Fig. 8b). We next analyzed 
lymphocytes from draining lymph nodes 7 days after the final NK 
cell injection. NK cells that had been pre-treated with lipids showed 
lower IFN-γ production and granzyme B expression in vivo, com-
pared to control NK cells (Fig. 8c,d). Thus, lipid accumulation in 
NK cells impairs NK cell effector functions in vivo, resulting in a 
failure to reduce tumor growth. To examine the effects of obesity on 
tumor growth in vivo, we fed wild-type mice a HFD for 12 weeks 
and injected B16 cells in week 10. As expected, weight gain was sig-
nificantly greater in HFD-fed mice (Fig. 8e). Obese mice had more 
rapid and severe tumor development than lean mice (Fig. 8f). We 
next examined the tumor-infiltrating lymphocytes and found that 
NK cells were significantly reduced in tumors in obese mice, both 
in percentage and in density (Fig. 8g,h) Furthermore, the tumor size 
was inversely correlated with the number of tumor-infiltrating NK 
cells (Fig. 8i), confirming our observation that NK cells have a pro-
tective effect against tumor growth. In line with the data that obesity 
inhibits NK cell functions, we found that the NK cell compartment 
in the tumors of obese mice was functionally defective, producing 
significantly less IFN-γ than in the tumors of lean mice (Fig. 8j). 
Together, our data show that the metabolic and functional defects 
in NK cells induced by obesity impair effective antitumor responses 
in vivo, resulting in increased tumor growth in obesity.
Discussion
It is now well accepted that obesity causes immune dysregulation, 
but most studies have so far focused on increased inflammation that 
interferes with insulin signaling and ultimately contributes to type 2 
diabetes. Our findings show that in addition to increased inflamma-
tion, obesity also impairs antitumor activity by cytotoxic lympho-
cytes. Chronic elevation of circulating FFAs, including palmitate, 
is a hallmark of obesity and has been linked to the development 
of insulin resistance17,35. We show that in obesity NK cells also take 
up lipids from the environment, which interferes with their cellular 
bioenergetics, inducing metabolic paralysis. This occurs through 
interference with mTOR–PPAR pathways. When mTOR is active, 
PPARα /δ -mediated lipid pathways are inhibited, but in obesity, the 
PPARα /δ target genes are highly upregulated, potentially as a mech-
anism to deal with lipotoxic environments. However, upregulation 
of PPARα /δ inhibits mTOR-mediated glycolysis as well as down-
stream transcription of cytotoxic granules and IFN-γ production. 
We also show that the mTOR pathway and glycolysis are essential 
for the step in the NK cell cytotoxic process that requires polariza-
tion of the MTOC and lytic granules to the tumor synapse, enabling 
efficient tumor killing. Thus, we have identified a mechanism of 
NK cell dysfunction in murine and human obesity, whereby NK 
cells isolated directly ex vivo from individuals with obesity lack the 
metabolic requirements to kill tumor cells. Furthermore, in mouse 
models, lipid-induced metabolic dysfunction was sustained in vivo 
and resulted in increased tumor burden.
It was found recently that NK ILC1 cells are resident and abun-
dant in adipose tissue and respond dynamically to changes in the 
diet and the ensuing weight loss or weight gain36–39. NK cells that 
infiltrate adipose tissue in obesity36, together with adipose-resident 
NK cells, have an important role in regulating adipose macrophage 
populations through cytokine production37,38 and direct cytotox-
icity36. Some of these studies highlighted the dysregulation of NK 
cells in obesity, suggesting that they contribute to inflammation and 
insulin resistance. In addition, in obese adipose tissue, NK cell cyto-
toxic functions against ‘stressed’ macrophages were also impaired. 
These studies highlight the dysregulation in adipose NK cells 
induced by obesity, leading to an overall inflammatory environment. 
Thus, obesity causes a seemingly paradoxical state of chronic low-
grade inflammation coupled with immunosuppression, similar to 
that reported for chronic inflammation and immunosuppression in 
other situations, including cancer40, spinal cord injury41 and sepsis42. 
Indeed, it has been found that sepsis-induced inflammation and 
immunosuppression are caused by metabolic paralysis character-
ized by loss of both glycolytic and oxidation metabolism43, similar 
to our findings in human obesity.
The realization that metabolism controls cell function in health 
and disease has led to a resurgent interest in cellular metabolism, 
with the ultimate goal of targeting metabolism therapeutically. 
Our study highlights the interdependence of cellular and systemic 
metabolism in immune regulation. The metabolic state of the 
organism affects the immune system through altered fuel supplies 
and cellular metabolism used by immune cells. This in turn regu-
lates immune cell function, which we now know can subsequently 
regulate whole-body metabolism, such that an immunometabolic 
loop exists between systemic and cellular metabolism in the organ-
ism. Our data raise the question of whether other scenarios of 
metabolic disorder may affect NK cells in a similar way. NK cells 
have a central role in antitumor immunity; however, a recent study 
of 18,000 tumor cases showed that resting or senescent NK cells 
in the tumor environment are associated with poor prognosis44. 
Our study provides insight into the metabolic requirements of NK 
cells to effectively kill tumor cells at the cellular level. In the tumor 
microenvironment where the tumor is consuming glucose and has 
high rates of glycolysis, tumor-infiltrating NK cells may be glucose 
deprived, leading to their inability to turn on mTORC1 and polarize 
lytic granules. Studies have suggested that treatment with rapamy-
cin, which inhibits mTORC1 and glycolysis, may be a useful strategy 
to restrict tumor growth, as it would limit the increased Warburg 
glycolytic metabolism in tumor cells. However, our data suggest that 
rapamycin treatment, if untargeted, would also impair the ability of 
NK cells to kill tumor cells. Furthermore, our data show that obesity 
is analogous to rapamycin treatment in terms of NK cell functions. 
This is likely to impact the ability of the innate immune system to 
respond to foreign or damaged cells, and may partly explain the 
increased risk of infection and cancer in individuals with obesity3,4.
Despite increased public awareness, the prevalence of obesity 
and related diseases continues to rise. Therefore, there is an urgent 
need to understand the pathways by which obesity leads to other 
diseases, and to develop new strategies to prevent their progres-
sion. Our results highlight immunometabolic pathways as a target 
to reverse immune defects in obesity and suggest that metabolic 
reprogramming of NK cells may improve their antitumor activity 
in human obesity.
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Methods
Mice. Male C57BL/6 mice were purchased from Jackson Laboratory or Harlan 
Laboratories. For obesity studies, mice were fed a HFD (60% calories from fat, 
Research Diets) for 8–13 weeks. Mice were bred in our specific-pathogen-free 
facilities at Harvard Medical School or Trinity College Dublin. All animal work 
was approved by and in compliance with the Institutional Animal Care and Use 
Committee guidelines of The Dana Farber Cancer Institute and Harvard Medical 
School or the Trinity College Dublin university ethics committee and the Health 
Products Regulatory Authority Ireland.
B16 tumor model. Female C57BL/6 mice were purchased from Harlan 
Laboratories. Mice were co-housed and randomized after tumor induction. 
The B16F10 mouse melanoma cell line was purchased from the American Type 
Culture Collection (ATCC). B16 cells (2 × 105 cells per mouse) were injected 
subcutaneously (s.c.) into the right flank. For HFD studies, mice were fed a HFD 
(45% calories from fat, Research Diets) for 12 weeks and tumor cells were injected 
after 10 weeks. For the adoptive transfer studies, mice were injected s.c. with NK 
cells (1.2–2 × 106 cells per mouse) or PBS into the tumor site on days 3, 7, and 11 
post tumor induction. Tumor growth was recorded every 2–3 days and animals 
were killed when tumors measured 15 mm in diameter (D). Tumor size was 
calculated using the following formula: (D1)2 × (D2/2), D1 being the smaller value 
of the tumor diameter. For flow cytometric analysis, tumors and draining lymph 
nodes were dissected 15–17 days after tumor induction, and tumors were digested 
with DNase I (20 units (U) per ml; Sigma-Aldrich) and collagenase D (1 mg ml–1; 
Roche) in RPMI-1460 for 1 h and red blood cells lysed using ammonium chloride 
lysis buffer. Single-cell suspensions, prepared using a 100 μ m nylon mesh, were 
stimulated with phorbol 12-myristate 13-acetate (PMA; 10ng ml–1; Sigma-Aldrich), 
ionomycin (500 ng ml–1; Sigma-Aldrich) and brefeldin A (BFA; 5 μ g ml–1; Sigma-
Aldrich) for 4 h at 37 °C. Cells were stained with LIVE/DEAD Fixable Aqua Dead 
Cell Stain (Life Technologies) and fluorochrome-conjugated antibodies for CD45, 
CD19, CD3, NKp46, and NK1.1, then fixed, permeabilized and incubated with 
antibodies for IFN-γ and granzyme B. Data were acquired using a LSRFortessaTM 
(BD) flow cytometer and analyzed with FlowJo v10 software.
Preparation of NK cells for in vivo transfer. For expansion of NK cells, single-cell 
suspensions of murine spleens were prepared and lysed with ammonium chloride 
lysis buffer. NK cells were cultured in IL-15 (10 ng ml–1; Peprotech) and isolated as 
described previously12. On day 6, NK cells were treated with or without lipids (100 
μ M palmitate + 100 μ M oleate; Sigma Aldrich) for 24 h and subsequently activated 
with IL-12 (25 ng ml–1; R&D), IL-15 (50 ng ml–1) and IL-18 (5 ng ml–1; R&D) for 
another 18 h without removing the lipids. NK cells were washed in PBS prior to  
in vivo transfer.
Microarray. NK cells were sorted on a FACSAria (BD) by the Flow Cytometry 
Core of The Dana-Farber Cancer Institute. Cells were double sorted to > 95% 
purity and collected into TRIzol (Invitrogen). Sample processing and data analysis 
were performed as described previously45. Expression plots were produced with 
GenePattern.
Human subjects. Ten milliliters of peripheral blood were obtained from healthy 
donors and patients with obesity attending the weight loss clinic at Brigham and 
Women’s Hospital, Boston medical Center, or St. Vincent’s University Hospital 
Dublin (mean age 47, range 24–60 years; mean BMI 48). All blood samples were 
obtained with written informed consent. The ethics committee at Boston Medical 
Center, Brigham and Women’s Hospital, and St. Vincent’s University Hospital 
Dublin, granted approval for this study.
Cell culture. Human peripheral blood mononuclear cells were isolated from 
healthy volunteer donors by ficoll density gradient separation using ficoll-paque 
(GE Healthcare). Primary NK cells were purified by positive selection using 
the NK cell purification kit (Miltenyi Biotec). NK cells were then cultured with 
RPMI 1640 (Life Technologies) supplemented with 10% heat-inactivated fetal 
bovine serum (Life Technologies), 1 ng ml–1 IL-15 (Peprotech). The YT-indy 
immortalized NK cell line and the human NK target cell lines K562 and 721.221 
were cultured in RPMI 1640 medium (Life Technologies) supplemented with 
10% heat-inactivated fetal bovine serum (Life Technologies), 100 units (U) per 
ml penicillin and 100 μ g ml–1 streptomycin (Life Technologies). The cell culture 
was performed at 37 °C and 5% CO2. For lipid treatment, stock solutions of 
sodium palmitate (Sigma-Aldrich) and sodium oleate (Sigma-Aldrich) were made 
at 25 mg ml–1 in methanol. Palmitate and oleate were dried in a glass tube with 
pulsed air, then resuspended in NK cell culture medium. The lipid solutions were 
finally gently sonicated for 2 to 5 min in a water bath sonicator. Freshly isolated 
NK cells were incubated for 36 to 48 h in complete medium supplemented with 
sodium palmitate (Sigma-Aldrich) or a mixture of sodium palmitate and sodium 
oleate (Sigma-Aldrich). For cytokine stimulation assays, NK cells were cultured 
with IL-2 (50 μ g ml–1) and IL-12 (20 ng ml–1) (Peprotech) for 18 h at 37 °C in NK 
cell culture medium. For mouse PPAR experiments, splenocytes were cultured 
with low-dose IL-15 (10 ng ml–1) in the presence or absence of the agonists for  
6 days. For human PPAR studies, purified human NK cells were cultured in  
low-dose IL-15 (1 ng ml–1) in the presence of agonists or antagonists for 5 days. 
Drugs used to culture NK cells with in this study are: rapamycin (20 or 100 nM; 
Tocris), Torin 1 (250 μ M; Selleck Chemicals), etomoxir (200 μ M; Tocris), 2-DG 
(30 μ M; Sigma-Aldrich) SL0101-1 (10 nM; Cayman), PPARα agonist WY14643 
(10 μ M), PPARδ agonist GW501516 (10 μ M), PPARα antagonist GW6471  
(10 μ M), and PPARδ antagonist GSK3787 (10 μ M).
Antibodies. Antibodies with the following specificities were obtained from 
BioLegend: anti-CD2 (RPA-2.10), anti-CD56 (HCD56), anti-IFN-γ (4S.B3),  
anti-CD107a (H4A3), anti-CD3 (OKT3), anti-PRF-1 (dg9) and anti-granzyme  
B (GB11). Mouse antibodies: anti-CD45 BV605 (30-F11), anti-CD3 BV650 (17A2), 
anti-NKp46 BV711 (29A1.4), anti-NK1.1 BV421 (PK136), anti-IFN-γ PerCP/Cy5.5 
(XMG1.2). Anti-Perforin (Pf-80/164) was purchased from Mabtech, the anti-
Pericentrin from Abcam, the anti-p-S6 (Ser235/236) from cell signaling and the 
Anti-granzyme B PE-Cy7 (NGZB) from eBioscience. Secondary antibodies donkey 
anti-mouse and rabbit coupled to fluorescent Alexa probed were purchased from 
Jackson Immunoresearch.
Cytotoxicity assay. For NK cells from blood of obese and lean donors, isolated 
NK cells were cultured with K562 cells at a ratio of 10:1 for 4 h at 37 °C. NK 
cell cytotoxicity was determined using the CytoTox-Fluor cytotoxicity assay 
(Promega), following the manufacturer’s instructions. For NK cell cytotoxicity 
assay by flow cytometry, target cells were labeled with 1 μ M CellTraceviolet (Life 
technologies) or 2 μ M CellVue Maroon (Ebioscience) and then mixed with NK 
cells at various NK:target ratios in NK cell culture medium in a 96-well plate 
(Corning). Anti-LAMP-1 conjugated with alexa 488 or alexa 647 (BioLegend) and 
monensin (BioLegend) were added to measure NK degranulation. The cells were 
then centrifuged to synchronize NK:target conjugate formation and incubated at 
37 °C for 1 to 2 h. Cells were then washed with cold PBS. The percentage of dead 
target cells was measured with propidium iodide (Pi) staining (Sigma Aldrich) by 
flow cytometry.
Oxygen consumption rate and extracellular acidification rate measurement. 
XF-24 or XFe-96 Extracellular Flux Analyzers (Seahorse Bioscience) were used 
for measurement of OCR and ECAR. Purified NK cells were plated at 5 × 105 cells 
per well for the 24-well Seahorse or 2 × 105 cells per well for the 96-well Seahorse 
analyzer in Seahorse plates coated with CellTak (BD pharmingen). The OCR and 
ECAR were measured in XF RPMI Seahorse medium supplemented with 10 mM 
glucose and 2 mM L-glutamine in response to oligomycin (2 μ M), FCCP (1 μ M), 
rotenone (100 nM) plus antimycin (4 μ M), 2-DG (30 mM) or etomoxir (200 μ M) 
(Sigma-Aldrich). OXPHOS, glycolysis and glycolytic capacity were calculated as 
follows:
= − ∕OXPHOS [OCR] [OCR]basal rotenone antimycin A
=Maximum respiratory rate [OCR] FCCP
= − −Glycolysis [ECAR] [ECAR]basal 2 DG
=Glycolysis capacity [ECAR] oligomycin
= −Spare glycolytic reserve [ECAR] [ECAR]oligomycin basal
Immunoblot analysis. For immunoblot analysis, cells were collected, washed 
twice with ice-cold PBS and lysed at 1 × 107 cells per ml in lysis buffer containing 
50 mM Tris-HCl pH 6.7, 2% SDS, 10% glycerol, 0.05% bromphenol blue, and 
1 μ M dithiothreitol. Samples were denatured at 95 °C for 10 min, separated by 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to a 
polyvinylidene difluoride membrane.
Flow cytometry and cell sorting. Single-cell suspensions, of blood or from cell 
culture, were obtained and incubated with Fc receptor-blocking antibody before 
being stained on ice. Dead cells were excluded by live/dead staining using 7-AAD, 
or Zombie Aqua (BioLegend) for fixed and permeabilized cells. For sorting and 
analysis of NK cells, a dump gate with F4/80 was used to eliminate nonspecific 
staining. Antibodies conjugated to fluorescein isothiocyanate, phycoerythrin, 
phycoerythrin-indotricarbocyanine, peridinine chlorophyll protein complex 
5.5, allphycocyanin, or allophycocyanin-indotricarbocyanine were as follows: 
CD45, CD3, NK1.1, NKp46, F4/80, and 7AAD. Intracellular staining was 
performed using a fixation and permeabilization buffer (eBioscience). For IFN-
γ production measurement, cells were treated with brefeldin A (eBioscience). 
Assessment of glucose uptake was performed by incubation of NK cells with 50 μ 
M 2-NBDG (2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose; 
Life Technologies) in RPMI 1640 (Life Technologies) for 30 to 60 min at 37 °C. 
Assessment of lipids was performed by incubation of cells with LipidTox 
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neutral lipid stain (Life Technologies) or Bodipy 495/515 (Life Technologies) as 
recommended by the manufacturer. Stained cells were analyzed on a FACSCanto 
I or FACSCanto II cytometer (BD Biosciences). Cell doublets were excluded by 
comparison of side-scatter width to forward-scatter area. Flow cytometry data were 
analyzed with FlowJo v10 software (Tree Star).
Immunostaining and microscopy. For single-cell imaging, cells were adhered 
to a 0.1% poly-l-lysine (Sigma-Aldrich) coated glass coverslips by cytospin. For 
conjugate imaging, NK cells and target cells K562 or 721.221 were co-incubated 
at a NK:target ratio 2:1 for 20 min. Conjugates were then gently adhered to 
coated coverslips by centrifugation. Cells were fixed for 15 min in PBS with 3.7% 
paraformaldehyde (PFA; Electron Microscopy Sciences), washed, incubated for 
10 min with 50 mM NH4Cl, permeabilized for 5 min with PBS and 0.2% Triton 
X100, and then blocked for 30 min with PBS, 10% FBS, and 0.05% Triton X100. 
Cells were then incubated with the indicated primary antibodies in blocking buffer 
for 1 h or 18 h then washed and incubated with fluorescent secondary antibodies 
(Jackson Immunoresearch). Cells were mounted in Fluoro Gel with DABCO 
(Electron Microscopy Sciences). Cells were analyzed on a Nikon TE2000-U 
inverted microscope equipped with the laser-scanning C1 confocal system using 
a Plan Apochromat 60× /1.40 NA oil objective. Image analysis and colocalization 
quantifications were carried out using National Institutes of Health ImageJ 
software. The localization of the pericentrin staining at the synapse was used to 
determine the polarization of NK cells. For each replicate of each experiment, a 
minimum of 100 NK cells was counted. All images were processed with Adobe 
Photoshop Software and Adobe Illustrator.
Statistics. Results are expressed as the mean ± s.e.m. or ± s.d. The statistical tests 
used were the unpaired Student’s t-test using Welch’s correction for unequal 
variances, one-way analysis of variance followed by Tukey’s post-hoc test, two-way 
analysis of variance followed by a Bonferroni test and chi-squared test. P ≤ 0.05 was 
considered to denote significance. No data points or mice were excluded.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the 
corresponding author upon reasonable request.
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main 
text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND 
variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Clearly defined error bars 
State explicitly what error bars represent (e.g. SD, SE, CI)
Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection FACS Diva has been used to collect flow cytometry data.  
Wave Desktop version 2.6 has been used to collect Seahorse data.
Data analysis GraphPad Prism 6 has been used to analyze the data.  
Expression plots were produced with GenePattern. 
Kegg pathway analysis were analyzed with Kegg software. 
FlowJo v10 has been used to analyze flow cytometry data.  
Wave Desktop version 2.6 has been used to analyze Seahorse experiments. 
ImageJ has been used for confocal images. 
Powerpoint has been used to edit western blot images. 
Adobe Photoshop has been used to edit confocal images.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers 
upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
Provide your data availability statement here.
Field-specific reporting
Please select the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences  Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/authors/policies/ReportingSummary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size Human Samples: When possible a minimum of 10 samples lean and obese were used for each experiment. Number of sample depends 
preliminary data which were used to calculate power calculations on the minimum sample size. As some samples were used for multiple 
measurements, for example all samples were used for NK cell levels, so there is increased sample size here as it combined all collections. 
Mouse studies: Power calculations were used to determine the minimum sample size. For HFD experiments, at least 5 mice per group per 
experiment were used. For the B16 tumor model, 15 mice (Figure 8B-D) or 5 (Figure 8E-J) mice per group were used.  
In vitro experiments including lipid and drug treatment were performed  each time with at least one obese and one lean matched donor to 
compare. Experiments were repeated 2-5 times with different donors to verify the phenotype. 
Data exclusions Data were excluded when human cells were poor quality, for example decreased viability (>20%) due to the freezing or thawing procedure. 
Exclusion criteria were not pre-established. No murine data were excluded from the analysis. 
Replication All experimental findings were reliably reproduced.  In many instances, the experiments have been pooled (as indicated).  
 
Figure 1: All experiments with different samples were reproducible.  
Figure 2: Various donors gave reproducible results. 
Figure 3a-c: 2 to 3 experiments, reproducible. 
Figure 3d: 10 replicates, 8 were reproducible, 2 didn't show changes phenotype. Thought to be due to extended length of experiment and 
other possibly due to donor.  
Figure 3e: 4 replicates, all reproducible.  
Figure 4a: 3 replicates, all reproducible. 
Figure 4b-c: 1 to 2 replicates, all reproducible. 
Figure 4d-e: 2 replicates, all reproducible. 
Figure 4f: All samples with different donors were reproducible.  
Figure 5a: 2 replicates, all reproducible. 
Figure 5b: All samples with different donor were reproducible.  
Figure 5c-e: 5  replicates, all reproducible. 
Figure 5e: 3  replicates, all reproducible. 
Figure 5g-i: All samples with different donors were reproducible. 
Figure 5j-k: 1 experiment, n=3 (HFD) n=5 (SFD) mice 
Figure 5l-q: 3 experiments (2 reproducible, 1 failed), 3-4 technical replicates per experiment 
Figure 6a: 1 experiment, reproducible.  
Figure 6b-d: 3 replicates, all reproducible. 
Figure 6e: 1 exemplary experiment of 4, all reproducible.   
Figure 6f: 4 experiments, all reproducible.  
Figure 6g: 5 experiments, all reproducible 
Figure 6h-n: 5 experiments, all reproducible 
Figure 6o: 4 experiments, all reproducible 
Figure 7a-b: 4 replicates, all reproducible 
Figure 7c: All samples with different donors were reproducible  
Figure 7d: 2 replicates, all reproducible 
Figure 7e: 1 experiment, reproducible.  
Figure 7f-g: 3 replicates, all reproducible. 
Figure 7h: 4 replicates, 3 reproducible,  1 failed. 
Figure 7i-j: 2 replicates, all reproducible 
Figure 8a: 4 experiments, reproducible 
Figure 8b-d: 2 experiments (pooled), reproducible 
Figure 8e-j: 1 experiment, 5 mice per group
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Randomization Peripheral blood was  obtained  from healthy donors and obese patients. Healthy lean donors have a BMI ranging from 19-25 while Obese 
patients have a BMI over 33. For mice, littermate controls were ear punched in order to generate experimental groups. In the B16 tumor 
model, mice were randomized into groups after tumor cell injection. 
Blinding For human samples, when possible, the order of acquiring the sample during imaging and flow cytometry was hidden for the investigator 
during the acquisition of all samples and the gating of results. The the samples were identified into groups at the stage of entering the data 
into the statistical package. 
For mouse experiments, investigators were not blinded during data collection and analysis. 
Reporting for specific materials, systems and methods
Materials & experimental systems
n/a Involved in the study
Unique biological materials
Antibodies
Eukaryotic cell lines
Palaeontology
Animals and other organisms
Human research participants
Methods
n/a Involved in the study
ChIP-seq
Flow cytometry
MRI-based neuroimaging
Antibodies
Antibodies used Human: 
Anti-CD56-APC (HCD56) / BioLegend / 318310 / #B225195  
Anti-IFNγ-Alexa488 (4S.B3) / BioLegend / 502515 / #B197426  
Anti-IFNγ-FITC (4S.B3) / BioLegend / 502506 / #B179400  
Anti-CD107a-APC (H4A3) / BioLegend / 328620 / #B168399 
Anti-CD107a (H4A3) / BioLegend / 328602 / #B156594  
Anti-CD3-PerCP Cy5.5 (OKT3) / BioLegend / 317336  
Anti-PRF-1-PE (dg9) / BioLegend / 308106 / B160766  
Anti-GZMB-FITC (GB11) / BD Bioscience / 560211 / #6168965  
Anti-Perforin (Pf-80/164) / Mabtech / 3465-3-250  
Anti-Pericentrin (N/A)/ Abcam / ab4448   
Anti-p-S6(Ser235/236)-PE (D57.2.2E) / Cell Signaling / 5316 / #7 and #8   
 
Mouse:  
Anti-CD19 PE-CF594 (1D3) / BD Biosciences / 562291  
Anti-CD45-BV605 (30-F11) / BioLegend / 103139  
Anti-CD3-BV650 (17A2) / BioLegend / 100229  
Anti-NKp46-BV711 (29A1.4) / BioLegend / 137621  
Anti-NK1.1-BV421 (PK136) / BioLegend / 108731  
Anti-IFN-gamma-PerCP/Cy5.5  (XMG1.2) / BioLegend / 505821  
anti-GZMB-PE-Cy7 (NGZB) / eBioscience / 25-8898-80 
Validation Human antibodies: Validated by manufacturer using human  PBMCs  
Mouse antibodies: Validated by manufacturer using C57BL/6  or BALB/c splenocytes
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) Cells lines K562, YT-INDY and 721.221 were obtained from Dr. Michael Brenner's Lab. Cell line B16.F10 was purchased from 
the ATCC.
Authentication None of the cell lines have been authenticated. 
Mycoplasma contamination Cell lines were not tested for mycoplasma infection. However, Imaging studies with DNA staining (Hoechst) didn't show 
additional small nucleus that could reveal the presence of mycoplasma. 
Commonly misidentified lines
(See ICLAC register)
No commonly misidentified cell lines were used. 
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Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals C57Bl/6J (WT) were purchased from Jackson Laboratory and maintained in specific-pathogen-free animal facilities at Brigham 
and Women’s Center for Comparative Medicine. In obesity experiments, male mice were used. Mice were 5-6 weeks old at the 
start of the experiments. In tumor experiments, C56Bl/6J (WT) female mice purchased from Envigo were used. Mice were 6-8 
weeks old at the start of the experiments. All animal work was approved by and was in compliance with the Institutional Animal 
Care and Use Committee guidelines of Brigham and Women’s Hospital and Harvard Medical School, and in Trinity Biomedical 
Sciences Institute.
Wild animals N/A
Field-collected samples N/A
Human research participants
Policy information about studies involving human research participants
Population characteristics Peripheral blood were obtained from healthy donors and obese patients attending the weight loss clinic at Brigham and 
Women’s Hospital, Boston medical Center or St. Vincent’s University Hospital Dublin, Ireland (mean age 47, range 24–60 years; 
mean BMI 48). The ethics committee at Boston Medical Center, Brigham and Women’s Hospital, Boston and St. Vincent’s 
University Hospital, Dublin granted approval for this study.
Recruitment We collected patients attending the weight management clinic, and a study coordinator collected blood for all patients that 
agreed to participate in the study. There was no selection bias, other than they had to have a BMI>30.
Flow Cytometry
Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation Human peripheral blood mononuclear cells were isolated from blood (10ml sample or leukopack collars) by Ficoll density 
gradient separation using ficoll-paques (GE Healthcare). Primary NK cells were purified by positive selection using the NK cell 
purification kit (Miltenyi Biotec).  
For surface staining, cells were washed twice with PBS and filtered through a 70um filter. Cells were then stained with NIR-LIVE/
DEAD (Life Technologies) for 20 minutes then washed with PBS, 2% FBS, twice. Cells were then stained with antibodies diluted in 
PBS, FBS 2% for 0.5 to 1H at 4C. Cells were then washed twice before data collection. For intracellular staining, following surface 
staining, cells were fixed (20 minutes) and permeabilized (20 minutes) (Ebioscience). Fixed cells were then incubated with 
antibodies for 0.5 to 1H at 4C. Cells were then washed twice before data collection.  
For cytokine production assays, cells were stimulated with indicated stimulus and then treated with brefeldin A for 4 to 6 hours 
before sample processing.  
For cytotoxic assays, target cells were pre-stained with cell trace violet (Life technologies) or Cell Vue Maroon (Ebioscience). 
Target and NK cells were then co-incubated together with or without Monensin (Ebioscience) and anti-CD107a antibody for 2 to 
4 hours. Two to 5 minutes before data collection, samples were stained with Propidium Iodide.  
For mice: 
Spleens and lymph nodes were strained through a 70μm cell strainer and spun. Pellets from all tissues were subjected to red 
blood cell lysis and subsequently resuspended in flow cytometry buffer (2% FBS and 0.02% NaN3 in phenol-free DMEM) for 
further staining. Tumors and draining lymph nodes were typically dissected 15-17 days after tumor induction and tumors 
digested with DNAse I (20 U/ml; Sigma-Aldrich) and collagenase D (1 mg/ml; Roche) in RPMI-1460 for 1H and red blood cells 
lysed using ammonium chloride lysis buffer. Single cell suspensions, prepared using a 100 μm nylon mesh, were stimulated with 
phorbol 12-myristate 13-acetate (PMA; 10 ng/ml; Sigma-Aldrich), ionomycin (500 ng/ml; Sigma-Aldrich) and brefeldin A (BFA; 5 
μg/ml; Sigma-Aldrich) for 4H at 37ºC. Cells were stained with LIVE/DEAD® Fixable Aqua Dead Cell Stain (Life Technologies) and 
fluorochrome-conjugated antibodies for CD45, CD19, CD3, NKp46, and NK1.1, then fixed, permeabilized and incubated with 
antibodies for IFNγ and granzyme B. 
Instrument BD Bioscience CANTO I and BD Bioscience CANTO II and BD Bioscience Fortessa
Software BD FACSDIVA  and FLOWJO (V10) software were used for data collection and data analysis respectively.
Cell population abundance For cytotoxicity assays, a minimum of 2,000 target cells were recorded per replicate. For others assays, a minimum of 10,000 NK 
cells were recorded per replicate. For human sample analysis, a minimum of 5,000 NK cells were recorded.  For microarray 
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analysis, a minimum of 30,000 NK cells were sorted. For tumor studies, B16 cells (2 x 105 cells/mouse) were injected 
subcutaneously (s.c.) into the right flank. On days 3, 7 and 11 post tumor induction, mice were injected s.c. with NK cells (1.2 – 2 
x 106 cells/mouse) or PBS into the tumor site.
Gating strategy In general: Global cell population is gated on FSC-A/SSC-A. Single cells are gated on FSC-A/FSC-H. When appropriate, live cells - 
using Aqua or NIR LIVE/DEAD Aqua or NIR - are gated. The dead population is determined using cells pretreated with detergent 
(Tween20, Triton X100) to induce major cell death as a positive control. NK cells were gated as CD56+/CD3- or NK1.1+NKp46
+CD3- in mice.  
The IFNg+ and p-S6+ populations were determine using the corresponding negative population in non-stimulated cells or 
fluorescence minus one controls. 
Cell Trace Violet or Cell vue maroon population were gated using a non stained sample.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
